Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 824-830

  Leon A ^a   Martinez, E ^a   Sarasa, M ^a   Lopez Y ^a   Mallolas, J ^a   De lazzari, E ^a   Laguno, M ^a   Milincovic, A ^a   Blanco, J l ^a   Larrousse, M ^a   Lonca, M ^a   Gatell, J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Body composition; Hypercholesterolaemia; Hypertriglyceridaemia; Pharmacokinetic parameters

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; KALETRA MELTREX; LAMIVUDINE; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; METABOLIC PARAMETERS; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BLOOD CHEMICAL ANALYSIS; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR;

EID: 34548793978     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm285     Document Type: Article

References (32)

1. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
2. Miller KD, Jones E, Yanovski JA et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998; 351: 871-5.
3. Lo JC, Mulligan K, Tai VW et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-70.
4. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999; 353: 2893-9.
5. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-36.
6. Cvetkovic RS, Goa KL. Lopinavir/ritonavir. Drugs 2003; 63: 769-802.
7. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-4.
8. Martinez E, Domingo P, Galindo MJ et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004; 38: 1017-23.
9. Martinez E, Mocroft A, Garcia-Viejo MA et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001; 357: 592-8.
10. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 10-4.
11. Murphy R, Zhang J, Hafner R et al. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, AACTG 5110. In: Abstracts of the Twelfth rence on Retroviruses and Opportunistic Infections, Boston, MI, SA, 2005. Abstract 45LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
12. Cameron DW, Becker S, King MS et al. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/ lamivudine nucleoside regimen. J Antimicrob Chemother 2007; 59 957-63.
13. Gutiérrez F, Padilla S, Masia M et al. Changes in body fat composition alter 1 year of salvage therapy with lopinavir/ ritonavir-containing regimens and its relationship wiht lopinavir plasma ooncentrations. Antivir Ther 2004; 9: 105-13.
14. González de Requena D, Blanco F, Garcia-Banayas T et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDs 2003; 17: 443-5.
15. Gutiérrez F, Padilla S, Navarro A et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy. J Acquir Immune Defic Syndr 2003; 33: 594-600.
16. Clevenbergh P, Garraffo R, Dellamonica P. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clin Trials 2003; 4: 330-6.
17. Torti C, Quirós-Roldan E, Regazzi-Bonora M et al. Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. J Acquir Immune Defic Syndr 2004; 35: 324-6.
18. Negrado E, Moltó J, Burger D et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 2005; 38: 47-52.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatmnent Panel III). JAMA 2001; 285: 2486-97.
20. Haarbo J, Gotfredson A, Hassaguer C et al. Validation of body composition by dual energy X-ray absorpmetry (DEXA). Clin Physiol 1991; 11: 331-41.
21. Sarasa-Nacenta M, López-Púa Y, Mallolas J et al. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 2001; 757: 325-32.
22. Boffito M, Amaudo I, Raiteri R et al. Clinical use of lopinavir/ ritonavir in a salvage therapy setting: Pharmacokinetics and pharmacodynamics. AIDS 2002 16: 2081-3.
23. Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27: 902-8.
24. Lal R, Hsu A, Granneman GR et al. Mulliple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. In: Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 1998. Abstract 647. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
25. Koch G. The use of nonparametric methods in the statistical analysis of the two period change-over design. Biometrics 1972; 28: 577-88.
26. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-22.
27. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomised trial. JAMA 2004; 292: 191-201.
28. Moyle G, Sabin C, Cartledge J et al. A 48-week, randomised, open-label comparative study of Tenofovir DF vs Abacavir as substitutes for a Thymidine analogue in persons with lipoatrophy and sustained virological suppression on HAART. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MI, USA, 2005. Abstract 44LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
29. Kaletra [prescribing information]. Abbott Laboratories, Abbott Park, Illinois, USA, 2002.
30. Benson CA, Deeks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185: 599-607.
31. Haubrich RH, Riddler S, DiRienzo G et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2007. Abstract 38. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
32. Cameron DW, da Silva B, Arribas J et al. Significant sparing of peripheral lipostrophy by HIV treatment with LPV/r+ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2007. Abstract 44. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.